Guggenheim Issues Positive Forecast for Sarepta Therapeutics (NASDAQ:SRPT) Stock Price

Sarepta Therapeutics (NASDAQ:SRPT) had its price target raised by Guggenheim from $148.00 to $150.00 in a research report released on Thursday,Benzinga reports. They currently have a buy rating on the biotechnology company’s stock.

Several other brokerages have also commented on SRPT. Jefferies Financial Group assumed coverage on Sarepta Therapeutics in a research report on Monday, October 21st. They set a “buy” rating and a $165.00 price objective on the stock. Citigroup reduced their price target on shares of Sarepta Therapeutics from $176.00 to $160.00 and set a “neutral” rating on the stock in a research report on Thursday, August 8th. Needham & Company LLC restated a “buy” rating and issued a $205.00 price objective on shares of Sarepta Therapeutics in a report on Thursday. Robert W. Baird reduced their target price on shares of Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating on the stock in a report on Thursday. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $182.00 price target on shares of Sarepta Therapeutics in a research note on Monday, October 21st. One equities research analyst has rated the stock with a hold rating, twenty have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $181.33.

Sarepta Therapeutics Trading Up 1.0 %

Shares of Sarepta Therapeutics stock opened at $121.61 on Thursday. The company has a 50 day simple moving average of $125.92 and a two-hundred day simple moving average of $132.91. The firm has a market cap of $11.60 billion, a PE ratio of 97.29 and a beta of 0.81. Sarepta Therapeutics has a 1 year low of $75.85 and a 1 year high of $173.25. The company has a debt-to-equity ratio of 1.05, a current ratio of 3.90 and a quick ratio of 3.19.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its earnings results on Wednesday, August 7th. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.01 by $0.06. Sarepta Therapeutics had a net margin of 7.43% and a return on equity of 11.72%. The company had revenue of $362.90 million during the quarter, compared to analyst estimates of $394.38 million. During the same period in the previous year, the business earned ($0.27) earnings per share. The firm’s quarterly revenue was up 38.9% compared to the same quarter last year. Analysts expect that Sarepta Therapeutics will post 1.48 earnings per share for the current fiscal year.

Insider Activity at Sarepta Therapeutics

In related news, Director Michael Andrew Chambers purchased 37,038 shares of the firm’s stock in a transaction that occurred on Friday, August 16th. The stock was bought at an average cost of $133.80 per share, with a total value of $4,955,684.40. Following the completion of the purchase, the director now directly owns 284,034 shares in the company, valued at approximately $38,003,749.20. This represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In other news, CFO Ian Michael Estepan sold 5,985 shares of the business’s stock in a transaction on Friday, August 30th. The shares were sold at an average price of $137.36, for a total transaction of $822,099.60. Following the sale, the chief financial officer now owns 33,946 shares in the company, valued at approximately $4,662,822.56. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Michael Andrew Chambers purchased 37,038 shares of the firm’s stock in a transaction that occurred on Friday, August 16th. The stock was acquired at an average price of $133.80 per share, with a total value of $4,955,684.40. Following the completion of the purchase, the director now owns 284,034 shares in the company, valued at $38,003,749.20. This represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 7.70% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Sarepta Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Innealta Capital LLC purchased a new position in shares of Sarepta Therapeutics during the second quarter valued at approximately $31,000. New Covenant Trust Company N.A. purchased a new position in Sarepta Therapeutics during the first quarter valued at $32,000. Huntington National Bank raised its stake in Sarepta Therapeutics by 150.9% during the third quarter. Huntington National Bank now owns 291 shares of the biotechnology company’s stock valued at $36,000 after buying an additional 175 shares during the last quarter. Nkcfo LLC bought a new stake in Sarepta Therapeutics in the second quarter worth $43,000. Finally, Riggs Asset Managment Co. Inc. grew its stake in shares of Sarepta Therapeutics by 33.3% in the second quarter. Riggs Asset Managment Co. Inc. now owns 300 shares of the biotechnology company’s stock worth $47,000 after acquiring an additional 75 shares during the last quarter. Hedge funds and other institutional investors own 86.68% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.